3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
9
Stomach Neoplasms
6
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Solid Tumor
3
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Muscle Invasive Bladder Cancer
1
Interventions
Oxaliplatin
21
Capecitabine
17
Fluorouracil
15
Irinotecan
11
Radiotherapy
10
Leucovorin
8
Cetuximab
6
Bevacizumab
6
Gemcitabine
5
oblimersen
3
fludarabine
3
aldesleukin
3
Nivolumab
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
labetuzumab
2
dehydroftorafur
2
conatumumab
2
Tomography, X-Ray Computed
2
Receptor Protein-Tyrosine Kinases
2
Radiation
2
Panitumumab
2
Neoadjuvant Therapy
2
Magnetic Resonance Imaging
2
Interleukin-2
2
Gefitinib
2
Electrocardiography
2
Diphenhydramine
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Rectal Neoplasms
×
tislelizumab
×
Clear all
NCT07561060
2026-05-01
TNTIT
Fudan University
Phase 1/2
Recruiting
50 enrolled